Arcturus Therapeutics Holdings Inc. [NASDAQ: ARCT] stock went on an upward path that rose over 10.66% on Friday, amounting to a one-week price increase of more than 7.03%. The company report on January 6, 2021 that Arcturus Therapeutics to Present at Upcoming Investor Conference.
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that the Company will participate in a panel discussion taking place at the 13th Annual Biotech Showcase™ Investor Conference:.
Infectious Disease – COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace.
Over the last 12 months, ARCT stock rose by 600.10%. The one-year Arcturus Therapeutics Holdings Inc. stock forecast points to a potential upside of 20.84. The average equity rating for ARCT stock is currently 2.30, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $1.72 billion, with 22.94 million shares outstanding and 21.44 million shares in the current float. Compared to the average trading volume of 1.97M shares, ARCT stock reached a trading volume of 1692748 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Arcturus Therapeutics Holdings Inc. [ARCT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ARCT shares is $91.54 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ARCT stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley Securities have made an estimate for Arcturus Therapeutics Holdings Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 19, 2021. While these analysts kept the previous recommendation, B. Riley Securities raised their target price from $138 to $77. The new note on the price target was released on January 15, 2021, representing the official price target for Arcturus Therapeutics Holdings Inc. stock. Previously, the target price had yet another raise to $118, while Wells Fargo analysts kept a Overweight rating on ARCT stock. On December 29, 2020, analysts decreased their price target for ARCT shares from 79 to 69.
The Average True Range (ATR) for Arcturus Therapeutics Holdings Inc. is set at 9.51, with the Price to Sales ratio for ARCT stock in the period of the last 12 months amounting to 166.59. The Price to Book ratio for the last quarter was 6.35, with the Price to Cash per share for the same quarter was set at 12.96.
ARCT Stock Performance Analysis:
Arcturus Therapeutics Holdings Inc. [ARCT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.03. With this latest performance, ARCT shares gained by 71.06% in over the last four-week period, additionally plugging by 32.23% over the last 6 months – not to mention a rise of 600.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARCT stock in for the last two-week period is set at 52.18, with the RSI for the last a single of trading hit 56.45, and the three-weeks RSI is set at 51.02 for Arcturus Therapeutics Holdings Inc. [ARCT]. The present Moving Average for the last 50 days of trading for this stock 77.35, while it was recorded at 67.91 for the last single week of trading, and 53.73 for the last 200 days.
Insight into Arcturus Therapeutics Holdings Inc. Fundamentals:
Arcturus Therapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.20 and a Current Ratio set at 11.20.
ARCT Stock EPS
With the latest financial reports released by the company, Arcturus Therapeutics Holdings Inc. posted -0.76/share EPS, while the average EPS was predicted by analysts to be reported at -0.53/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -43.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ARCT.
Arcturus Therapeutics Holdings Inc. [ARCT] Insider Position Details
There are presently around $1,310 million, or 69.10% of ARCT stock, in the hands of institutional investors. The top three institutional holders of ARCT stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 2,495,842, which is approximately 30.071% of the company’s market cap and around 12.00% of the total institutional ownership; HEALTHCOR MANAGEMENT, L.P., holding 1,594,452 shares of the stock with an approximate value of $115.53 million in ARCT stocks shares; and STATE STREET CORP, currently with $113.06 million in ARCT stock with ownership of nearly 504.698% of the company’s market capitalization.
84 institutional holders increased their position in Arcturus Therapeutics Holdings Inc. [NASDAQ:ARCT] by around 7,826,538 shares. Additionally, 52 investors decreased positions by around 2,715,316 shares, while 10 investors held positions by with 7,535,128 shares. The mentioned changes placed institutional holdings at 18,076,982 shares, according to the latest SEC report filing. ARCT stock had 29 new institutional investments in for a total of 914,283 shares, while 20 institutional investors sold positions of 822,132 shares during the same period.